- Immutep (IMM) is granted a new patent by the Chinese Patent Office for its lead product candidate, eftilagimod alpha
- The new patent relates to methods of use of efti in combination with a chemotherapy agent to treat cancer
- The new Chinese patent follows grants for Japan, Europe and the United States, and remains valid until October 3, 2028
- Immutep was up 0.85 per cent, trading at 59 cents at 12:30 pm AEDT
Immutep (IMM) has been granted a new patent by the Chinese Patent Office.
The new patent is owned by Immutep S.A.S. and exclusively licensed to Immutep’s partner in China, EOC Pharma.
The patent, entitled “Use of recombinant LAG-3 or the derivatives thereof for eliciting a monocyte immune response,” forms part of a broad portfolio of patents for the company’s lead product candidate, eftilagimod alpha (efti).
“We are investing in the development of efti for the local market in China and are very pleased with the steps being taken by our partner, Immutep, to build a broad portfolio of patent families around this unique candidate,” EOC Pharma CEO Xiaoming Zou said.
The new patent relates to methods of use of Immutep’s efti in combination with a chemotherapy agent to treat cancer.
The new Chinese patent follows grants for Japan, Europe and the United States.
“We are making good progress building our global patent estate around our LAG-3 development pipeline, including lead candidate efti which has delivered promising clinical data in various settings,” Immutep CEO, Marc Voigt said.
The new patent provides protection in mainland China, valid until October 3, 2028.
Immutep was up 0.85 per cent, trading at 59 cents at 12:30 pm AEDT.